Gastroparesis Treatment Market Analysis / Research Report 2022 – Promising Pipelines Developed By Key Players –


DUBLIN–(BUSINESS WIRE)–The Report “Gastroparesis Treatment Market, By Drug, By Type, By Route Of Administration, By Distribution Channel, By Region – Size, Share, Outlook and Opportunity Analysis, 2022- 2030” has been added to from offer.

Strong and promising pipelines developed by key gastroparesis treatment players are expected to drive the growth of the gastroparesis treatment market. For example, in October 2021, Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with unmet medical needs, announced that the company had received the US Food and Drug Administration (FDA) clearance to conduct a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A clinical trial study conducted by Processa Pharmaceuticals, Inc. for PCS12852 is in Phase 2.

PCS12852 is a 5-hydroxytryptamine 4 (5-HT4) receptor agonist. PCS12852 is indicated for the treatment of gastroparesis. Additionally, an increase in the number of patents for gastroparesis is likely to augment the market growth. For example, in April 2018, EVOKE PHARMA, a specialty pharmaceutical company focused on the treatment of gastrointestinal (GI) diseases, announced that the European Patent Office had issued a decision granting the European Union patent (EU) no. 2747561 for Gimoti, covering formulations of metoclopramide for intranasal administration for the treatment of symptoms associated with diabetic gastroparesis, specifically for women. Moreover, the strategies adopted by the key players such as acquisition, partnership, etc. are likely to drive the growth of the market.

For example, in October 2016, Allergan, a pharmaceutical company, acquired Motus Therapeutics, a gastrointestinal disease subsidiary of Rhythm Holding Company, following positive results from the Phase 2b trial of Motus’ investigational treatment for diabetic gastroparesis.

Main characteristics of the study:

  • This report provides an in-depth analysis of the Global Gastroparesis Treatment Market, Market Size (Million US$) and Compound Annual Growth Rate (CAGR%) for the forecast period (2022-2030), by considering 2021 as the reference year.

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

  • This study also provides key insights into the market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.

  • It profiles leading players of the global Gastroparesis Treatment Market based on the following parameters: Company Highlights, Product Portfolio, Key Highlights, Financial Performance, Strategies.

  • The information in this report would enable marketers and managing authorities of companies to make informed decisions regarding their future product launches, type upgrades, market expansion and marketing tactics.

  • The Global Gastroparesis Treatment Market report is targeted at various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants and financial analysts.

  • Stakeholders would have an ease in decision-making through various strategy matrices used in the analysis of global gastroparesis treatment

Market dynamics, regulation and trend analysis

  • Drivers

  • Constraints

  • Opportunities

  • Impact analysis

  • PEST analysis

  • Regulatory scenario

  • Pipeline analysis

  • New approach for the treatment of gastroparesis

  • Treatment guidelines

  • New product launches

  • Key development

  • Covid 19-Impact analysis

Major companies covered in this study include

  • Processa Pharmaceuticals, Inc.

  • Company Highlights

  • Product portfolio

  • Highlights

  • Financial performance

  • Strategies


  • Neurogastrx, Inc.

  • Vanda Pharmaceuticals Inc.

  • ANI Pharmaceuticals, Inc.

  • Takeda Pharmaceutical Company Limited

  • GlaxoSmithKline plc.

  • Otsuka Holdings Co., Ltd.

  • CinDome Pharma, Inc.

  • Therapeutic PTC

  • Pfizer, Inc.

  • Teva Pharmaceutical Industries Ltd.

  • Atlantic Health Care

  • Salix Pharmaceuticals

Detailed segmentation:

Global Gastroparesis Treatment Market, By Drug:

  • Metoclopramide

  • Erythromycin

  • Domperidone

  • Others

Global Gastroparesis Treatment Market, By Type:

  • Diabetic gastroparesis

  • Idiopathic gastroparesis

  • Post-surgical gastroparesis

Global Gastroparesis Treatment Market, By Route:

Global Gastroparesis Treatment Market, By Distribution Channel:

  • Hospital pharmacies

  • Retail pharmacies

  • Online pharmacies

Global Gastroparesis Treatment Market, by Region:

  • North America

  • WE

  • Canada

  • Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

  • Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Russia

  • The rest of Europe

  • Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea


  • Rest of Asia-Pacific

  • Middle East

  • GCC

  • Israel

  • Rest of the Middle East

  • Africa

  • South Africa

  • central Africa

  • North Africa

For more information about this report visit


Comments are closed.